Similar articles for PMID: 30785325

Year	Number of Results
1994	1
1995	1
1998	1
2002	3
2003	1
2004	1
2005	3
2006	2
2007	4
2008	5
2009	6
2010	3
2011	3
2012	1
2013	7
2014	19
2015	22
2016	25
2017	25
2018	20
2019	15
2020	17
2021	8
2022	3
2023	4
2024	0

1

New Medications for the Treatment of Diabetes.

Garg SK, Giordano D. Garg SK, et al. Diabetes Technol Ther. 2019 Feb;21(S1):S160-S171. doi: 10.1089/dia.2019.2513. Diabetes Technol Ther. 2019. PMID: 30785325 Review. No abstract available.

2

NICE guidance on dapagliflozin with insulin for type 1 diabetes.

Adler AI, Ting S, Dent R, Latimer N. Adler AI, et al. Lancet Diabetes Endocrinol. 2019 Oct;7(10):750-751. doi: 10.1016/S2213-8587(19)30265-7. Epub 2019 Sep 2. Lancet Diabetes Endocrinol. 2019. PMID: 31488391 Free article. No abstract available.

3

Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.

Boeder S, Edelman SV. Boeder S, et al. Diabetes Obes Metab. 2019 Apr;21 Suppl 2(Suppl 2):62-77. doi: 10.1111/dom.13749. Diabetes Obes Metab. 2019. PMID: 31081593 Free PMC article. Review.

4

Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.

Bloomgarden Z. Bloomgarden Z. J Diabetes. 2013 Sep;5(3):225-7. doi: 10.1111/1753-0407.12065. Epub 2013 Jul 1. J Diabetes. 2013. PMID: 23714218 No abstract available.

5

SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.

Lingvay I. Lingvay I. Endocr Pract. 2017 Jul;23(7):831-840. doi: 10.4158/EP161725.RA. Epub 2017 Mar 23. Endocr Pract. 2017. PMID: 28332871 Review.

6

The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.

Whalen K, Miller S, Onge ES. Whalen K, et al. Clin Ther. 2015 Jun 1;37(6):1150-66. doi: 10.1016/j.clinthera.2015.03.004. Epub 2015 Apr 16. Clin Ther. 2015. PMID: 25891804 Review.

7

Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes.

Williams DM, Stephens JW. Williams DM, et al. Expert Opin Pharmacother. 2015;16(15):2373-9. doi: 10.1517/14656566.2015.1088830. Expert Opin Pharmacother. 2015. PMID: 26389773 Review.

8

The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor.

Feng X, Gu Q, Gao G, Yuan L, Li Q, Zhang Y. Feng X, et al. Ann Endocrinol (Paris). 2020 Oct;81(5):476-481. doi: 10.1016/j.ando.2020.07.1113. Epub 2020 Aug 18. Ann Endocrinol (Paris). 2020. PMID: 32822653 Clinical Trial.

9

Case Report: DKA with Lower-than-Expected Blood Glucose in the Setting of SGLT2 Inhibitor Use.

Voskertchian A, Milanes L. Voskertchian A, et al. Am Fam Physician. 2021 Feb 15;103(4):200. Am Fam Physician. 2021. PMID: 33587584 Free article. No abstract available.

10

Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.

Wanner C. Wanner C. Nat Rev Nephrol. 2018 Feb;14(2):78-80. doi: 10.1038/nrneph.2017.182. Epub 2018 Jan 8. Nat Rev Nephrol. 2018. PMID: 29307892 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

181 results

Results by year